LinkedInDavid Glover

David Glover

Independent Consultant in Biotechnology and Pharmaceuticals

Location
Cambridge, United Kingdom
Industry
Biotechnology
Current
  1. Alacrita LLP
Previous
  1. MedCell Bioscience Ltd,
  2. Zyentia,
  3. Cambridge Antibody Technology
Education
  1. University of Cambridge
Websites
353connections

Join LinkedIn & access David's full profile

Join LinkedIn & access David's full profile. It's free!

As a LinkedIn member, you'll join 300 million other professionals who are sharing connections, ideas, and opportunities.

  • See who you know in common
  • Get introduced
  • Contact David directly
353connections
Alacrita LLP

Alacrita LLP

Associate Consultant

– Present

View full profile

Background

Summary

Highly respected pharmaceutical physician with unparalleled experience of biological drugs. I help small companies ( pharma, biotech and institutional ) in all aspects of drug development from preclinical into clinical trials through to market. I assist companies with assessment of potential in-licensing candidates, programmes, with due diligence and review of R&D portfolios and assessing overall commercial prospects for products. I offer a fresh pair of eyes to look at a project, programme or problem for clients, or provide a different perspective on business plans. I also coach and advise on presentations to potential investors.

I have worked in virtually every therapeutic area and am currently most interested in regenerative medicine, hospital / specialist products and medical devices.Presentation skills, data assimilation and presentation, and communication are some of my key strengths. I have significant media experience, for example in the aftermath of the TGN1412 clinical trial disaster. I played a major role in the industry response helping make future first in man studies of novel biologics safer for volunteers.

Specialties: Biological drugs , Monoclonal Antibodies, Regenerative Medicine, Advanced medical therapies ,Hospital / specialist products : especially Clinical trials , Preclinical product development , overall Development strategy , Due Diligence projects, independent expert , portfolio review , presentation skills , assessment of overall commercial prospects, considerable media experience ,

Experience

Associate Consultant

Alacrita LLP
– Present (4 years 1 month)

Consultancy projects for Alacrita clients, working with Principals and other Alacrita Associate Consultants. Recent projects have been antibody related such as
- Due diligence
- Target evaluation
- Therapeutic area review
- Strategic product development

Non Exec Director

MedCell Bioscience Ltd
(3 years 4 months)

Pioneering spinout from Royal Veterinary College, London. Autologous bone marrow derived mesenchymal stem cells for repair of tendon injury in horses.
- Non Executive Director for over 3 years and Chairman for more than a year
- Led development of strategy and plans to apply technology to humans
- Led company to successful meetings at EMEA and MHRA
- Led acquisition of Novathera, a regenerative medicine Imperial College spinout company
- Oversaw sale of company assets to Quy Bioscience Ltd

Non Exec Chairman

Zyentia
(2 years 4 months)Babraham, Cambridge

Oxford University spinout company with expertise in protein folding / misfolding.
- Non Executive Chairman
- Refocussed company on core assets of proprietary software
- Raised additional funding from shareholders
- Oversaw sale of assets and transfer of staff to Lonza Biologics

Chief Medical Officer

Cambridge Antibody Technology
(11 years)Cambridge

Pioneering human monoclonal antibody (mAb) company founded by David Chiswell and Greg Winter (MRC LMB) based upon phage display.
- Joined company as VP Medical Development, the first senior management appointee from industry
- Established Pre-Clinical and Clinical/ Regulatory departments
- Led human monoclonal antibody product development
- Helped float the company on London Stock Exchange in 1997
- Appointed to the Board as Chief Medical Officer and Executive Director in 1997
- Responsible for putting several human mAb drug candidates into man
- Led the deal with Genzyme on anti-TGF Beta mAbs in 1999
- Initiated the discussions with Astra-Zeneca which led to initial deal in 2004
- Director responsible for Health and Safety at the company
- Made several prize winning presentations for the company
- Company spokesperson on all product related matters
- Member of ABPI Board of Management 2001 - 4
- Helped raise over $250 million for company from share offerings and corporate deals

Medical Director

Schering-Plough UK
(6 years)Mildenhall and Welwyn Garden City

UK subsidiary of US Pharmaceutical company, based in New Jersey, in global top 20.
- Appointed as UK and Eire Medical Director reporting to UK general manager
- Led integration and reorganisation of UK based medical department
- Played leading role in achieving regulatory approval for Clarityn (loratadine)
- Key role in subsequent UK approvals for several products including flutamide, dilevalol, ceftibuten, mometasone, molgramostim, interferon alpha
- Member of US head office teams including cardiovascular and hepatitis task force
- European chairman for novel cholesterol lowering drug programme
- Overhauled the company procedures for approving promotional materials
- Actively involved with BrAPP on the national committee, chairing education sub committee
- Honorary Clinical Assistant at Addenbrooke's Hospital, Cambridge (to Dr. L. Shapiro) 1989- 1998

Clinical Research Physician

Merck Sharp and Dohme Ltd
(4 years 3 months)Hoddesdon

UK subsidiary of world leading US Pharmaceutical company, based in New Jersey.
- Appointed as clinical research physician in the UK cardiovascular team on MSDRL payroll
- Member of US head office cardiovascular team
- Responsible for clinical trials of ACE inhibitors enalapril post launch and lisinopril phase III onwards, also other cardiovascular products
- Played key role in UK approval for lisinopril
- Responsible for Medical approval of all cardiovascular product promotional materials
- Promoted to Director of Medical Affairs, Cardiovascular in 1997
- Played major role in market preparation and planning for Zocor (simvastatin)
- Honorary Clinical Assistant at the National Heart Hospital ( to Dr. K. Fox) 1985 -9

Courses

Skills

  • Clinical trials
  • Preclinical testing
  • biological drugs
  • Portfolio Management
  • Monoclonal Antibodies
  • Biotechnology
  • Pharmaceuticals
  • Clinical Development
  • Due Diligence
  • Clinical Research
  • Strategic Planning
  • Biopharmaceuticals
  • Team Building
  • Strategy Development
  • Named patients /...
  • Presentation Coaching
  • Pharmaceutical Industry
  • Clinical Trials
  • Healthcare
  • Strategy
  • GCP
  • Pharmacology
  • Medicine
  • CRO
  • Neuroscience
  • R&D
  • Medical Affairs
  • See 12+  See less

Education

University of Cambridge

MA MB BChir, Medicine

Gonville and Caius College

King Edwards School, Edgbaston

View David's full profile to...

  • See who you know in common
  • Get introduced
  • Contact David directly

Not the David Glover you're looking for? View more

Insights


People Also Viewed

LinkedIn members in United Kingdom:

  1. a
  2. b
  3. c
  4. d
  5. e
  6. f
  7. g
  8. h
  9. i
  10. j
  11. k
  12. l
  13. m
  14. n
  15. o
  16. p
  17. q
  18. r
  19. s
  20. t
  21. u
  22. v
  23. w
  24. x
  25. y
  26. z
  27. more